ESR1 and breast cancer: In the presence of agonist ligands, insights gained from ChIP-seq experiments have confirmed that PR causes the rapid redistribution or sequestration of ERα away from its pro-proliferative gene targets in breast cancer cells, resulting in a unique gene expression program that is associated with a good clinical outcome and culminating in cell cycle arrest [15,103].